Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss pill shows promise: daily semaglutide helps shed pounds

NCT ID NCT05035095

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a daily oral semaglutide tablet (50 mg) for weight loss in 667 adults with overweight or obesity. Participants took the pill or a placebo for 68 weeks, along with diet and exercise advice. The main goals were to measure percentage weight loss and how many people lost at least 5% of their body weight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide tablets
What this could lead to
If successful, this could provide a convenient daily pill option for significant weight loss in people with overweight or obesity.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to everyone. Side effects like nausea or vomiting are possible, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

667 people

The number who actually took part.

Started

Sep 2021

Finished

May 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, age greater than or equal to 18 years at the time of signing informed consent * Body mass index (BMI): greater than or equal to 27.0 kg/m\^2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease OR greater than or equal to 30.0 kg/m\^2 * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening * A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Capital Clin Res Ctr,LLC

    Olympia, Washington, 98502, United States

  • Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque-2

    Pessac, 33600, France

  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec

    Saint-Herblain, 44800, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-2

    Toulouse, 31054, France

  • Centre de Recherche Clinique Portes Du Sud

    Vénissieux, 69200, France

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Pomeranian Voivodeship, 81-338, Poland

  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.

    Lodz, 90-338, Poland

  • Centrum Zdrowia Metabolicznego Paweł Bogdański

    Poznan, Wielkopolskie Voivodeship, 60-589, Poland

  • Chiba University Hospital_Diabetes, Metabolism and Endocrinology

    Chiba-shi, Chiba, 260-8677, Japan

  • Clinical Trial Res Assoc,Inc

    Plantation, Florida, 33324, United States

  • Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR

    Hamburg, 22041, Germany

  • Dr. Milek medikum

    Hohenmölsen, 06679, Germany

  • East West Med Res Inst

    Honolulu, Hawaii, 96814, United States

  • Endocrinological Dispensary of Department of healthcare ser.

    Moscow, 119034, Russia

  • FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia

    Moscow, 117292, Russia

  • Federal Bureau for Medical and Social Expertise

    Moscow, 127486, Russia

  • Fondation Hôtel-Dieu

    Le Creusot, 71200, France

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7, Canada

  • Gabinet Leczenia Otylosci i Chorob Dietozaleznych

    Bialystok, Podlaskie Voivodeship, 15-281, Poland

  • Gentofte Hospital - Center for Klinisk Metabolisk Forskning

    Hellerup, 2900, Denmark

  • Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu-2

    Le Creusot, 71200, France

  • Higashi-shinjuku clinic

    Tokyo, 169-0072, Japan

  • Hvidovre Hospital Endokrinologisk forsknings afsnit 159

    Hvidovre, 2650, Denmark

  • InnoDiab Forschung GmbH

    Essen, 45136, Germany

  • Joint Stock Company "Medical technologies"

    Yekaterinburg, 620075, Russia

  • Joint Stock Company "Polyclinic Complex"

    Saint Petersburg, 190013, Russia

  • LLC "Clinic of new technologies in Medicine"

    Dzerzhinskiy, 140091, Russia

  • Leningrad Regional Clinical Hospital

    Saint Petersburg, 194291, Russia

  • Les Hopitaux de Chartres-Hopital Louis Pasteur

    Le Coudray, 28630, France

  • MZM Praxis Drs. Erlinger

    Stuttgart, 70378, Germany

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • NZOZ Przychodnia Specjalistyczna Medica

    Lublin, Lubelski, 20-538, Poland

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Obesity Research Unit

    Helsinki, 00014, Finland

  • Ocean West Research Clinic

    Surrey, British Columbia, V3Z 2N6, Canada

  • Praxis Dr. med. M. Esser

    Essen, 45219, Germany

  • Praxis Dr. med. Wenzl-Bauer

    Rehlingen-Siersburg, 66780, Germany

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, L8M 1K7, Canada

  • RED-Institut für medizinische Forschung und Fortbildung GmbH

    Oldenburg in Holstein, 23758, Germany

  • Rochester Clinical Research, Inc.

    Rochester, New York, 14609, United States

  • Seinäjoen keskussairaala

    Seinäjoki, 60220, Finland

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • Sjællands Universitetshospital, Køge - Medicinsk Afdeling

    Køge, Region Sjælland, 4600, Denmark

  • Slagelse Sygehus Ambulatorium for hjertesygdomme

    Slagelse, 4200, Denmark

  • StudyCor

    Jyväskylä, 40620, Finland

  • Suidoubashi Medical Clinic_Internal Medicine

    Chiyoda-ku, Tokyo, 101-0065, Japan

  • The Chappel Group Research

    Kissimmee, Florida, 34744, United States

  • The University of Penn Center

    Philadelphia, Pennsylvania, 19104-3317, United States

  • Tumen State Medical University

    Tyumen, Russia, 625023, Russia

  • Univ of Alabama Birmingham

    Birmingham, Alabama, 35233, United States

  • Velocity Clin Res Los Angeles

    Los Angeles, California, 90017, United States

  • Velocity Clinical Res-Dallas

    Dallas, Texas, 75230, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, L8L 5G8, Canada

  • Zentrum für klinische Studien Allgäu Oberschwaben

    Wangen, 88239, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.